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Vertex Pharmaceuticals Inc, in collaboration with Kissei 
Pharmaceutical Co Ltd, is developing VX-702, one of a series of 
second-generation, orally active p38 MAP kinase inhibitors, for 
the potential treatment of inflammation, rheumatoid arthritis and 
cardiovascular diseases. In June 2005, a phase II clinical trial of 
VX-702 was initiated in rheumatoid arthritis. In July 2006, 
Vertex was planning to file an IND in the second half of 2006. 
Introduction 
p38 MAP kinase (MAPK) is an intracellular, soluble proline-
targeted serine-threonine kinase which belongs to a large 
family of proteins that include extracellular regulated 
kinases (ERKs) and c-Jun N-terminal kinases (JNKs) 
[688537], [688545], [688587]. Thus far, four p38 isoforms have 
been identified, namely p38α, p38β, p38β and p38δ. The 
ubiquitous p38α has been the most extensively studied and 
is believed to be the most physiologically relevant in the 
regulation of the inflammatory response. While the role of 
the three other isoforms is not currently well understood, 
their primary sites of expression are known. Similar to p38α, 
p38β is also ubiquitously expressed, while p38γ is expressed 
predominately in skeletal muscle and p38δ is expressed 
primarily in the lung, kidney, testis, small intestine and 
pancreas [478666], [608092], [688545], [688587]. Activation of 
p38 MAPK occurs by the phosphorylation of the Thr-Gly-
Tyr (TGY) motif in the activation loop via MAPK kinase 
(MKK)-3 and MKK-6 in response to extracellular stimuli, 
such as environmental stress, cytokines, endotoxin (ie, 
lipopolysaccharide [LPS]), ultraviolet light and ischemia 
[478666], [608092], [688545], [688587]. The activation of p38 
MAPKs leads to gene transcription and translation, followed 
by an increase in production of inflammatory mediators, 
such as TNFα, IL-1β, cyclooxygenase (COX)-2, IL-6, IL-12 
and IFNγ [688537], [688545], all of which have been 
demonstrated to play important roles in autoimmune 
diseases such as rheumatoid arthritis (RA) and/or 
cardiovascular diseases. 
  
The pathogenesis of RA requires cytokine-mediated 
communication between T-helper type-1 (Th1) lymphocytes, 
macrophages, neutrophils, endothelial cells and osteoclasts. 
The activation and infiltration of these cells, as well as the 
production of inflammatory cytokines in the synovium, 
have been revealed to be p38 MAPK-dependent [491004]. 
Patients with RA exhibited increased activation of p38 
MAPK in the synovial lining layer and endothelial 
cells[547879]. In addition, the p38 MAPK pathway is rapidly 
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activated in rheumatoid synovial fibroblasts by TNFα and 
IL-1β, resulting in over-production of IL-6 and IL-8 [688636]. 
Inhibition of p38 MAPK was shown to significantly improve 
clinical severity scores, reduce bone destruction and 
cartilage loss, and reduce mRNA levels and the production 
of inflammatory mediators in models of experimental 
arthritis [688770], [688772], suggesting that therapy 
involving the inhibition of p38 MAPK may constitute a new 
therapeutic strategy for RA. 
 
Activation of p38 MAPK by pathological stressors, including 
ischemia, has been observed with cardiovascular diseases 
such as advanced heart failure [688631]. This leads to the 
activation of MAPK-activated protein kinase (MK)-2 
followed by the over-production of inflammatory cytokines 
(ie, TNFα, IL-1β and IL-6), which play an important role in 
the pathogenesis of some cardiovascular diseases (ie, 
myocardial infarction [MI] and congestive heart failure) 
[688631]. TNFα can also induce p38 MAPK activity [688631]. 
p38 activity may be involved in many aspects of cardiac 
pathology, including gene regulation, interstitial 
remodeling, contractility, energy metabolism, cardiac COX-2 
and prostaglandin biosynthesis, cardiac hypertrophy and 
endothelial dysfunction [505287], [688775]. Inhibition of p38 
activation was shown to decrease cardiomyocyte apoptosis 
and improve cardiac function after myocardial ischemia and 
reperfusion [688777], reduce hypertrophy and left 
ventricular (LV) dilatation, and increase LV contractility in 
the cardiomyopathic hamster model [688778], all of which 
suggest that strategies to block p38 activation may have an 
application in ischemic diseases and heart failure, including 
acute coronary syndromes (ACS). 
 
Evidence from X-ray crystallographic structures suggests 
that bound ATP directly interacts with the p38 hinge region 
residues His107 and Met109 to form a pair of hydrogen bonds 
with the adenine ring of ATP [688780]. Once p38 is 
activated, a gate uncovers the active site allowing optimum 
and efficient binding of ATP, thereby leading to the 
subsequent phosphorylation and activation of the enzyme 
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[688784]. To date, the development of p38 inhibitors has 
focused mainly on small-molecule ATP-competitive 
inhibitors. As a consequence, many inhibitors have been 
designed to take advantage of specific interactions that are 
located within or near the ATP binding site. So far, more 
than 150 patent applications from at least 30 pharmaceutical 
companies have claimed novel p38 inhibitors. The p38 
inhibitors can be divided into six groups; pyridinyl- and 
pyrimidyl-imidazoles and related structures, bicyclic 6,6-
heterocycles and related structures, N,N'-diaryl ureas and 
related compounds, substituted benzamides, diaryl ketones, 
and indole amides [688780]. 
 
More than 100 p38 MAPK inhibitors have been developed 
for the potential treatment of inflammatory and/or 
cardiovascular diseases, but the majority have been 
discontinued mainly due to undesirable side effects. VX-702, 
one of a series of second-generation, orally active p38 MAPK 
inhibitors, is under development by Vertex Pharmaceuticals 
Inc in collaboration with Kissei Pharmaceutical Co Ltd, for 
the potential treatment of inflammation, RA and 
cardiovascular diseases [435164], [512323], [688791]. 
Preliminary phase II results for the treatment of RA and 
ACS have been reported recently [592866], [654608]. 
Synthesis and SAR 
Vertex developed the first generation of p38 inhibitors, 
including VX-745, which was suspended from further 
development due to CNS toxicity. VX-745 had a 
pyrimidopyridazinone bicycle which formed the hydrogen 
bond to the linker residue and was directly connected to a 
phenyl ring in the gatekeeper pocket by a single sulfur atom 
spacer. A 2,6-diCl phenyl was attached to the bicycle and 
this was predicted to occupy the hydrophobic pocket of the 
concave floor [688791]. The structure of VX-702 has not been 
disclosed, but a Vertex patent application [WO-00214281] 
suggests that it is an N-pyridinyl-N-phenyl urea-based 
inhibitor. The SAR for the urea class is in contrast with most 
of the other p38 inhibitors that rely more heavily on the 
hydrogen bonding interaction with Met109 for potent p38 
activity. Additionally, because of their binding properties, 
this class of compounds tends to show high affinities and 
exhibit slow binding kinetics relative to other known p38 
inhibitors [688780]. 
Preclinical development 
In an ex vivo blood assay primed with LPS, VX-702  
dose-dependently inhibited the production of IL-6,  
IL-1β and TNFα (IC50 = 59, 122 and 99 ng/ml, respectively) 
[592866]. To determine the effects, if any, of VX-702 on 
platelet function alone, or in conjunction with other 
commonly used anti-platelet therapies, gel-filtered platelets 
were prepared from healthy individuals (n = 6) for an ex vivo 
study [516895], [688796]. This activation was completely or 
partially inhibited by pre-incubation with 1 µM of VX-702 
(IC50 = 4 to 20 nM). VX-702 had no effect on platelet 
aggregation induced by any of the p38 MAPK agonists, such 
as thrombin, SFLLRN, AYPGKF and collagen, in the 
presence or absence of platelet inhibitors, such as aspirin, 
heparin or apyrase. VX-702 did not directly cause platelet 
aggregation or induce Ca2+ mobilization, or affect basal 
aggregation induced by shear stress. In contrast, aspirin 
blocked thromboxane production, resulting in a significant 
inhibition of collagen-induced platelet aggregation. These 
results suggest that blocking p38 MAPK does not affect 
thromboxane production in human platelets. Unlike 
aspirin blockade of thromboxane production in platelets 
with aspirin, VX-702 does not significantly affect platelet 
function and would not be expected to contribute to an 
elevated risk of hematological side effects in treated 
patients [688796]. 
 
VX-702, at a dose of 0.1 mg/kg twice daily, was found to be 
equivalent to methotrexate (a commonly used disease-
modifying antirheumatic drug [DMARD]; also at  
0.1 mg/kg) in mouse collagen-induced arthritis. 
Furthermore, VX-702 (5 mg/kg, twice daily) was found to be 
equivalent to prednisolone (10 mg/kg, once daily) in the 
same model, as measured by the percentage inhibition of 
wrist joint erosion and an inflammation score [445056]. 
 
Male Sprague Dawley rats (n = 30) with myocardial damage 
after ischemia-reperfusion injury were randomized to 
receive either vehicle or VX-702 (5 or 50 mg/kg) [514348]. 
The results suggested that phosphor MK2 was markedly 
increased in the ischemic zone tissue compared with the 
non-ischemic zone tissue in the vehicle group. This effect 
was dose-dependently reduced in the VX-702 groups.  
VX-702 selectively inhibited activation of p38 MAPK after 
ischemia, with no effects on ERKs and JNKs. There were no 
differences in hemodynamic data and area at risk (AAR)/LV 
ratio between the three groups. The MI/AAR ratio was 
significantly reduced in the 50-mg/kg group compared with 
the other two groups. This study concluded that oral 
administration of VX-702 reduces myocardial damage after 
ischemia-reperfusion injury, suggesting that selective p38 
MAPK inhibition may play a therapeutic role in ACS. 
Metabolism and pharmacokinetics 
Healthy volunteers were administered VX-702 orally at 
doses of 2.5 to 80 mg (n = 5 to 8 per dose point) [592866]. The 
half-life was 16 to 20 h, with a median clearance of 3.75 l/h 
and a volume of distribution of 73 l/kg. Both the AUC and 
Cmax were dose proportional for VX-702, which was found to 
be predominantly renally cleared.  
Toxicity 
No data are currently available.  
Clinical development 
Phase I 
VX-702 was administered to 45 patients with ACS 
undergoing percutaneous coronary intervention (PCI) (5, 10, 
20 and 40 mg, at 3 and 24 h prior to PCI) [592866]. There was 
a dose-dependent reduction in C-reactive protein (CRP), a 
predictor of coronary heart disease, 1 month after patient 
discharge. A significant but variable reduction in serum IL-6 
was reported, and IL-1β production was inhibited in a 
pharmacodynamic assay. In addition there was a dose-
dependent reduction in neutrophils and plasma monocytes 
at days 2, 3 and 4 of the study, and also after 1 month. There 
was no significant elevation of liver function tests. 
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Phase II 
RA 
A randomized, double-blind, multicenter, 12-week, phase 
II clinical study was conducted in patients with moderate 
to severe RA (n = 278) some of whom were receiving 
DMARDs but none were receiving methotrexate or anti-
TNF therapies [654608]. Patients received either VX-702  
(5 or 10 mg) or placebo once daily for 12 weeks. Patients 
were evaluated for improvement in clinical signs and 
symptoms according to the American College of 
Rheumatology (ACR)20 criteria, which assesses 
improvements in tender and swollen joint counts, plus 
three of the following: patient pain assessment, patient 
global assessment, physician global assessment, patient 
self-assessed disability and acute-phase reactant 
(erythrocyte sedimentation rate or CRP). VX-702 treatment 
significantly reduced signs and symptoms of RA in a dose-
dependent manner, with 30, 38 and 40% of patients 
receiving placebo, 5 and 10 mg, respectively, achieving an 
ACR20 response at week 12 (p = 0.04). In addition, 32, 41 
and 44% of patients receiving placebo, 5 and 10 mg, 
respectively, achieved a moderate or good European 
League Against Rheumatism response (p = 0.01), which 
has three categories (good, moderate and non-responders) 
based on the assessment of disease activity using the 
disease activity score. Dose-dependent significant effects 
were also seen on tender joint counts (p = 0.007), swollen 
joint counts (p = 0.003) and morning stiffness (p = 0.03). 
 
In March 2006, Vertex expected to initiate clinical studies of 
VX-702 in combination with methotrexate for RA, including 
a 3-month, dose-ranging phase II study in more than 200 
patients [654608]. 
 
ACS 
A phase IIa double-blind, placebo-controlled, randomized 
study was designed to evaluate the safety and anti-
inflammatory effect of VX-702 in 45 patients with unstable 
angina undergoing PCI [564973]. Patients received VX-702 
(5, 10, 20 or 40 mg/day) 2 days prior to PCI and 3 days 
afterwards. CRP was lowered within 24 h of the first dose. A 
significant dose-dependent lowering was seen at 48 h after 
VX-702 treatment, with decreases of 37, 67, 71 and 63% in 
the 5-, 10-, 20- and 40-mg groups, respectively, compared 
with an increase of 98% in the placebo group. Decreased 
CRP was maintained for 4 weeks beyond the 5-day dosing 
schedule. 
Side effects and contraindications 
A 12-week study in patients with moderate to severe RA (n 
= 315) indicated that VX-702 (5 or 10 mg) was well tolerated 
[654608]. Premature discontinuations for adverse events 
were low (2, 5 and 10% in the placebo, 5- and 10-mg groups, 
respectively). No significant effects were observed from liver 
function tests. Gastroenteritis, nausea/vomiting, rash and 
renal impairment (increased serum creatinine levels to 1.2- 
to 1.5-fold of upper limit of normal) associated with VX-702 
treatment led to discontinuation in two patients. The most 
common adverse events were generally mild or moderate, 
and included infection (5 and 10% of placebo and VX-702 
patients, respectively), gastrointestinal disorders (6 and 8%, 
respectively), and skin disorders (0 and 9%, respectively). 
Ambulatory and 12-lead electrocardiographic monitoring 
revealed no differences in ventricular ectopic activity or 
cardiac arrhythmias between placebo and treated patients. A 
minimal (~ 1.5%) dose-dependent increase on digital 
electrocardiograms in the Fridericia rate-corrected QT 
interval (QTcF) was observed in the VX-702 treatment 
groups, from baseline to the end of treatment. No patient 
experienced a clinically significant increase in QTcF (defined 
as 60 ms, or ~ 15%) at any time in the study. 
 
VX-702 (5, 10, 20 or 40 mg) was well tolerated in 45 patients 
with unstable angina undergoing PCI [564973]. The 
frequency of adverse events, including bleeding, arrhythmia 
and liver enzyme abnormalities, were similar in the VX-702 
and placebo groups over a 4-week period. 
Patent summary 
As of October 2006, the structure of VX-702 had not been 
disclosed; however, Vertex had previously stated that VX-702 
was structurally distinct from the earlier p38 inhibitor, VX-745 
[445056], [450049]. The product case for VX-745 is  
WO-09827098, the first of ten PCT applications from Vertex 
claiming new compounds as p38 kinase inhibitors; the other 
applications being WO-09900357, WO-09958502,  
WO-09964400, WO-00017204, WO-00017175, WO-00170695, 
WO-00214281, WO-02092087 and WO-02100405. As VX-702 
has been disclosed to be structurally distinct from VX-745, it is 
probable that it is not disclosed in WO-09827098, but rather in 
one of the subsequent PCT applications. In August 2004, the 
process case WO-2004072038 was published, claiming 
methods for preparing p38 inhibitors, in particular, 
compounds disclosed in WO-09958502 and WO-00017175. If 
WO-2004072038 covers the preparation of VX-702, the product 
case for VX-702 is likely to be WO-09958502 or WO-00017175. 
Current opinion 
Activation of p38 MAPK is associated with the over-
production of proinflammatory mediators, including TNFα, 
IL-1β, COX-2, IL-6, IL-12 and IFNγ. Therefore, inhibition of 
p38 MAPK activity by VX-702 has the potential for the 
treatment of disorders, including a variety of inflammatory 
diseases such as RA, Crohn's disease and psoriasis, as well 
as cardiovascular diseases such as ACS. Preliminary clinical 
studies have shown promising results; VX-702 significantly 
reduced the signs and symptoms of RA over 12 weeks, and 
decreased CRP levels in patients with ACS. It was well 
tolerated with no observed liver function abnormalities.  
VX-702 was unable to cross the blood-brain barrier [422880], 
thus it may have little neurological adverse effects. It did not 
affect platelet function, and therefore may not cause the side 
effects of bleeding in treated patients [688796]. 
 
Of note, p38 MAPK has been involved in many mammalian 
cell processes including cell-cycle regulation, death, 
development and differentiation [688537]. As a consequence 
of the wide-ranging regulatory role of p38 MAPK in these 
diverse cellular processes, the possibility of adverse effects 
resulting from undesired pharmacological activity is the 
major concern for the p38 MAPK inhibitors. Many of these 
inhibitors have been reported to equally inhibit both the 
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p38α and p38β isoforms, and p38β inhibition may induce 
more unwanted off-target effects due to the divergent 
physiological roles of p38β.  
 
More than 100 p38 MAPK inhibitors have been 
investigated over the past decade, but the majority have 
not entered into clinical trials or have been withdrawn 
after initial clinical trials mainly due to undesirable side 
effects. For example, BIRB-796 (Doramapimod), an  
N-pyrazole urea derivative, was being developed by 
Boehringer Ingelheim GmbH. In a phase I clinical trial, 
BIRB-796 (20, 50 and 150 mg for 7 days) demonstrated a 
symptomatic dose-related rise in alanine transaminase and 
aspartate transaminase levels, primarily with the 150-mg 
dose [472871]. In a 14-day study with oral doses of 15 and 
30 mg twice daily, 9 of 48 individuals had alanine 
transaminase values above the upper limit of normal 
[472871]. Although phase II studies in RA, Crohn's disease 
and psoriasis were completed, BIRB-796 was discontinued 
from further development, perhaps due to the observed 
liver function abnormalities [608092], [688791]. AMG-548, a 
pyrimidinone compound that was being developed by 
Amgen Inc, was the most potent and efficacious p38 
inhibitor reported to progress to phase I studies. However, 
random liver enzyme elevations in a multidose study 
prevented further development of this drug [608092], 
[688791]. VX-745, the first generation p38 MAPK inhibitor 
developed by Vertex, had entered phase II trials for the 
treatment of RA [688784], but was discontinued in 2001 after 
the compound was shown to cross the blood-brain barrier 
and exhibit toxicity at high doses in animal studies [422880]. 
SCIO-469 (Scios Inc), a potent p38α inhibitor possibly 
derived from the indole amide class [688780], is currently 
undergoing phase II clinical trials for the treatment of pain, 
multiple myeloma and RA [608092]. Although results from 
phase I trials suggested that SCIO-469 was well-tolerated, 
there was a transient and mild light-headedness associated 
with the highest doses, suggesting that it may cross the 
blood-brain barrier. In contrast to these p38 inhibitors, VX-
702 may have a superior safety profile because of its inability 
to cross the blood-brain barrier and no reports of liver 
dysfunction, even though it has a similar urea structure to 
BIRB-796. However, the undesired common effects of p38 
inhibitors on liver, central nervous, immune (resulting in 
infection), cardiovascular and gastrointestinal systems 
should be kept in mind for future clinical trials of VX-702.  
 
With regard to efficacy, VX-702 effectively relieved signs 
and symptoms of RA but only showed modest improvement 
in the ACR20 response rate compared with placebo during 
the phase II clinical trial. This is possibly due to the ability of 
p38 MAPK inhibitors to not only inhibit the Th1 response 
(useful for the treatment of chronic inflammatory diseases), 
but also to decrease Th2 function which reduces the 
production of IL-4 and IL-10 (resulting in enhancement 
rather than amelioration of the underlying inflammatory 
response in Th1-driven diseases such as RA) [688537]. 
Furthermore, other members of the MAPK family (such as 
JNK) also play an important role in the pathogenesis of RA 
[688798], thus while the selective inhibition of p38 MAPK 
can diminish side effects, it may consequently compromise 
the efficacy for the treatment of RA. Inhibition of spinal p38 
may regulate peripheral inflammation [693122], and 
therefore the inability of VX-702 to cross the blood-brain 
barrier could decrease the anti-inflammatory effects. The 
efficacy of VX-702 on ACS is unclear; however, it has been 
reported to reduce CRP level in patients with ACS.  
 
There are currently limited published data available on  
VX-702 and reasons for this are unknown. It may reflect 
business consideration by the developer, as there is fierce 
competition for p38 inhibitor development between 
different pharmaceutical companies. 
 
In summary, VX-702 is well tolerated and significantly 
reduces inflammatory responses in the treatment of RA and 
ACS, but its clinical efficacy and safety remain to be further 
demonstrated. 
Commercial opinion 
Analysts from Wachovia Securities ascribed a low 
probability of success to the VX-702 program based on what 
they believe to be low results from the rheumatoid arthritis 
phase II study in combination with Vertex's announced 
delay on the start of a phase IIb trial until the second half of 
2007 [728603]. However, if launched in 2011, Wachovia 
estimated initial worldwide sales of US $221.4 million, to 
peak at US $750 million by 2013.  
 
Licensing 
Kissei Pharmaceutical Co Ltd 
By September 1997, Kissei had exercised an option for the development of p38 MAP kinase inhibitors and had entered into a 
three-year agreement with Vertex to develop these inhibitors, including VX-702 [386727]. Under the agreement, Kissei was to 
pay a license fee, research support and milestone payments up to US $22 million; Kissei gained exclusive rights in Japan and 
certain rights in south east Asia, and semi-exclusive rights in China, Taiwan and South Korea. Vertex retained US and 
European rights [386727], [399818]. In the fourth quarter of 2000, Kissei paid Vertex a US $1 million milestone payment for 
the advancement of VX-702 into preclinical studies [399818], [475831]. 
Development history 
Developer Country Status Indication Date Reference 
Vertex Pharmaceuticals Inc Europe Phase II Rheumatoid arthritis 12-JUN-05 606796 
Vertex Pharmaceuticals Inc US Phase II Cardiovascular disease 21-MAY-03 490502 
Kissei Pharmaceutical Co Ltd Japan Phase I Cardiovascular disease 31-DEC-05 649069 
Kissei Pharmaceutical Co Ltd Japan Phase I Inflammation 31-DEC-05 649069 
Vertex Pharmaceuticals Inc US Discovery Inflammation 24-OCT-00 386727 
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Literature classifications 
Biology 
Study type Effect studied Model Result Reference 
Ex vivo Activity Blood assay primed with 
LPS. 
VX-702 dose-dependently inhibited the production of 
IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/ml, 
respectively).  
592866 
In vivo Efficacy Mouse collagen-induced 
arthritis. 
VX-702 (at a dose of 0.1 mg/kg twice daily) had an 
equivalent effect as methotrexate (0.1 mg/kg). In 
addition, VX-702 (5 mg/kg twice daily) had an 
equivalent effect as prednisolone (10 mg/kg once 
daily), as measured by percentage inhibition of wrist 
joint erosion and inflammation score. 
445056 
In vivo Efficacy Ischemia-reperfusion injury 
model in male Sprague 
Dawley rats (n = 30) 
randomized to receive vehicle 
or VX-702 (5 or 50 mg/kg). 
VX-702 selectively inhibited activation of p38 MAPK 
after ischemia with no effects on ERKs and JNKs. 
The MI/AAR ratio was significantly reduced in the  
50-mg/kg group compared with the vehicle and  
5-mg/kg groups. 
514348 
In vitro Activity Gel-filtered platelets 
prepared from healthy 
individuals (n = 6). 
Pre-incubation of platelets with VX-702 (1 µM) 
completely or partially inhibited platelet agonist-
induced p38 activation (IC50 = 4 to 20 nM). No effect 
of VX-702 on platelet aggregation induced by any of 
the p38 MAPK agonists in the presence or absence 
of anti-platelet therapies occurried. 
688796 
Metabolism 
Study type Effect studied Model Result Reference 
In vivo  Pharmacokinetics Volunteers administered VX-702 
orally at doses of 2.5 to 80 mg  
(n = 5 to 8 per dose point). 
The half-life of VX-702 was 16 to 20 h, with 
a median clearance of 3.75 l/h and a 
volume of distribution of 73 l/kg. Both AUC 
and Cmax values were dose proportional for 
VX-702, which was predominantly renally 
cleared. 
592866 
Clinical 
Effect studied Model Result Reference 
Safety and efficacy A phase I, 5-day study of  
VX-702 (5, 10, 20 and 40 mg, 
at 3- and 24-h prior to PCI) 
administered to 45 patients 
with ACS undergoing PCI. 
There was a dose-dependent reduction in CRP 1 month 
after patient discharge. A significant but variable 
reduction in serum IL-6 was reported, as well as a dose-
dependent reduction in neutrophils and plasma 
monocytes.  
592866 
Safety and efficacy A phase II, randomized, 
double-blind, 12-week clinical 
trial in patients with moderate 
to severe RA (n = 278). 
Patients received either  
VX-702 (5 or 10 mg) or 
placebo once daily for 12 
weeks. 
VX-702 significantly reduced signs and symptoms of RA 
in a dose-dependent manner, with 30, 38 and 40% of 
patients receiving placebo, and 5 and 10 mg of VX-702, 
respectively, achieving an ACR20 response at week 12. 
In addition, 32, 41 and 44% of patients, respectively, 
achieved a moderate or good European League Against 
Rheumatism score. Dose-dependent, significant effects 
were also seen on tender joint counts (p = 0.007), 
swollen joint counts (p = 0.003) and morning stiffness  
(p = 0.03). 
654608 
Safety, tolerability and 
efficacy 
A phase IIa, double-blind, 
placebo-controlled, 
randomized study of VX-702 
(5, 10, 20 or 45 mg/day) 
administered for 2 days prior 
to PCI and 3 days afterwards 
in 45 patients with unstable 
angina undergoing PCI. 
CRP was lowered within 24 h of the first dose of  
VX-702. A significant dose-dependent lowering was 
observed at 48 h with decreases of 37, 67, 71 and 63% in 
the 5-, 10-, 20- and 40-mg VX-702 groups, respectively, 
compared with an increase of 98% in the placebo group. 
Decreased CRP remained at 4 weeks beyond the 5-day 
dosing schedule. VX-702 was well tolerated, and adverse 
events, including bleeding, arrhythmias and liver enzyme 
abnormalities, were similar in the drug and placebo 
groups in a 4-week period. 
564973 
Associated patent 
 
Title Inhibitors of p38. 
 
Assignee Individual 
 
Publication WO-00214281 21-FEB-02 
 
Priority US-2000 224719 11-AUG-00 
 
Inventors Cochran J, Galullo V, Bemis G. 
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